Title: Clinical Performance and Outcomes After Sphere Lens Transition

November 11, 2026 updated by: CooperVision International Limited (CVIL)

Clinical Performance and Patient Outcomes When Transitioning From Comfilcon A Sphere to Fanfilcon A Sphere Lenses.

To evaluate subjective and clinical outcomes after transitioning from one sphere soft contact lens to another over a one-month period.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • State of Mexico
      • México, State of Mexico, Mexico, CP 06760
        • Consultorio Optométrico
        • Contact:
          • Dr. Ruben Velazquez Guerrero, OD
          • Phone Number: +525528991976
          • Email: rubenvg@unam.mx

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Participants with eyes appropriate for the study being conducted
  2. They are at least 18 years of age.
  3. They understand their rights as a research participant and are willing and able to sign a Statement of Informed Consent.
  4. Current habitual wearer of Biofinity soft sphere contact lenses with contact lens power ranging from +8.00 to -12.00 DS.
  5. Anisometropia no greater than 1.50D, based on contact lens power spherical equivalent.
  6. Can achieve visual acuity of at least 0.1 logMAR (20/25) in each eye with contact lenses.
  7. Able to wear the study contact lenses for 6 days a week, minimum 8 hours a day.
  8. Can be fitted with the study contact lenses (Avaira Vitality® sphere).
  9. They agree not to participate in any other clinical research study while enrolled in this study.

Exclusion Criteria:

- 1. Anterior segment infection, inflammation or abnormality 2. Any active anterior segment ocular disease that would contraindicate contact lens wear 3. The use of systemic or ocular medications that would contraindicate contact lens wear 4. History of herpetic keratitis 5. History of refractive surgery or irregular cornea 6. Slit lamp findings that are more serious than grade 1 (ISO scale). 7. Inactive (i.e. ghost) vessels greater than 1 mm of penetration into the cornea 8. They have corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.

9. They have participated in a contact lens or contact lens care product clinical trial in the past 30 days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Refit to Fanfilcon A Sphere Contact Lens

Habitual wears of Confilcon A soft sphere contact lenses Refitted to Fanfilcon A sphere contact lense s and followed for one month.

Participants are refit from their habitual sphere soft contact lenses to fanfilcon A sphere contact lenses and wear the lenses for approximately one month according to the study protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective Comfort
Time Frame: Baseline, 1 week, and 1 month.

Subjective comfort on insertion (0-100 Visual analogue scale)

Baseline, 1 week, and 1 month.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MKTG-26-40

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe